Farther Finance Advisors LLC Has $82,000 Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Farther Finance Advisors LLC increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 273.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,538 shares of the company’s stock after buying an additional 3,323 shares during the quarter. Farther Finance Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $82,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in TEVA. Maple Rock Capital Partners Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 68.3% in the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after purchasing an additional 1,770,000 shares in the last quarter. Iron Triangle Partners LP boosted its holdings in Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after acquiring an additional 1,469,864 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $23,115,000. Davidson Kempner Capital Management LP grew its stake in shares of Teva Pharmaceutical Industries by 152.5% in the 2nd quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock worth $28,689,000 after acquiring an additional 1,066,150 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEVA has been the topic of several recent analyst reports. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays lifted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Finally, UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.11 on Wednesday. The firm has a market capitalization of $19.38 billion, a P/E ratio of -20.13, a PEG ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a one year low of $8.55 and a one year high of $19.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.59. The business has a fifty day moving average price of $17.91 and a 200-day moving average price of $17.18.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.